FINV vs. HRMY
FINV (FinVolution Group) and HRMY (Harmony Biosciences Holdings, Inc.) are both stocks. FINV operates in Credit Services (Financial Services), while HRMY operates in Biotechnology (Healthcare). Over the past 5 years, FINV returned -4.69%/yr vs 1.50%/yr for HRMY. At a 0.12 correlation, their price movements are largely independent.
Performance
FINV vs. HRMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FINV achieves a 2.28% return, which is significantly higher than HRMY's -7.91% return.
FINV
- 1D
- 1.62%
- 1M
- 1.82%
- YTD
- 2.28%
- 6M
- 1.69%
- 1Y
- -38.52%
- 3Y*
- 8.84%
- 5Y*
- -4.69%
- 10Y*
- —
HRMY
- 1D
- -2.10%
- 1M
- 12.03%
- YTD
- -7.91%
- 6M
- -14.93%
- 1Y
- 4.52%
- 3Y*
- -1.66%
- 5Y*
- 1.50%
- 10Y*
- —
FINV vs. HRMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
FINV FinVolution Group | 2.28% | -20.07% | 45.47% | 4.39% | 6.39% | 89.23% | 20.81% |
HRMY Harmony Biosciences Holdings, Inc. | -7.91% | 8.75% | 6.53% | -41.38% | 29.22% | 17.95% | -9.60% |
Correlation
The correlation between FINV and HRMY is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Aug 19, 2020 | 0.12 |
Fundamentals
FINV:
$1.29B
HRMY:
$2.03B
FINV:
CN¥8.34
HRMY:
$2.48
FINV:
4.09
HRMY:
13.88
FINV:
1.43
HRMY:
0.14
FINV:
0.68
HRMY:
2.25
FINV:
0.54
HRMY:
2.22
FINV:
CN¥13.24B
HRMY:
$899.11M
FINV:
CN¥10.21B
HRMY:
$688.25M
FINV:
CN¥2.61B
HRMY:
$221.74M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FINV vs. HRMY — Risk / Return Rank
FINV
HRMY
FINV vs. HRMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for FinVolution Group (FINV) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FINV | HRMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.90 | ||
| Sortino ratioReturn per unit of downside risk | -1.49 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 1.06 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | -0.71 | 0.10 | -0.81 |
| Martin ratioReturn relative to average drawdown | -0.96 | 0.18 | -1.14 |
Loading charts...
Drawdowns
FINV vs. HRMY - Drawdown Comparison
The maximum FINV drawdown since its inception was -89.76%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for FINV and HRMY.
Loading charts...
Drawdown Indicators
| FINV | HRMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.76% | -68.48% | -21.28% |
Max Drawdown (1Y)Largest decline over 1 year | -56.42% | -34.49% | -21.93% |
Max Drawdown (3Y)Largest decline over 3 years | -56.42% | -50.81% | -5.61% |
Max Drawdown (5Y)Largest decline over 5 years | -70.54% | -68.48% | -2.06% |
Current DrawdownCurrent decline from peak | -49.54% | -43.42% | -6.12% |
Average DrawdownAverage peak-to-trough decline | -54.09% | -35.27% | -18.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 41.69% | 18.73% | +22.96% |
Volatility
FINV vs. HRMY - Volatility Comparison
FinVolution Group (FINV) has a higher volatility of 19.10% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 11.05%. This indicates that FINV's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FINV | HRMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.10% | 11.05% | +8.05% |
Volatility (6M)Calculated over the trailing 6-month period | 33.29% | 30.44% | +2.85% |
Volatility (1Y)Calculated over the trailing 1-year period | 48.91% | 42.03% | +6.88% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 49.99% | 50.13% | -0.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.75% | 52.45% | +19.30% |
Dividends
FINV vs. HRMY - Dividend Comparison
FINV's dividend yield for the trailing twelve months is around 6.08%, while HRMY has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
FINV FinVolution Group | 6.08% | 5.30% | 3.49% | 4.39% | 4.13% | 3.45% | 4.49% | 7.17% |
HRMY Harmony Biosciences Holdings, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
FINV vs. HRMY - Financials Comparison
This section allows you to compare key financial metrics between FinVolution Group and Harmony Biosciences Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
FINV vs. HRMY - Profitability Comparison
FINV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported a gross profit of 2.43B and revenue of 3.19B. Therefore, the gross margin over that period was 76.3%.
HRMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.
FINV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported an operating income of 526.49M and revenue of 3.19B, resulting in an operating margin of 16.5%.
HRMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.
FINV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported a net income of 412.55M and revenue of 3.19B, resulting in a net margin of 12.9%.
HRMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.
Frequently Asked Questions
FINV and HRMY have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FINV has higher volatility (19.10%) compared to HRMY (11.05%). In terms of maximum drawdown, FINV dropped -89.76% vs HRMY's -68.48%.
HRMY currently has the higher Sharpe Ratio (0.08 vs -0.82), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FINV and HRMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer